Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2016 · 10-K
Revenue$1.10M$1.10M−15.5% vs Q4 2015 Net Income-$4.95M-$4.95MN/M vs Q4 2015 EPS Diluted-$0.05-$0.05N/M vs Q4 2015 Gross Profitderived$1,105,000−15.4% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income-$11,253,000N/M Operating Cash Flowderived-$8,852,000N/M Margins · derivedGross margin100.2%+0.2 pt vs Q4 2015
Operating margin-1020.2%+641.9 pt vs Q4 2015
Net margin-448.3%+585.9 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 16, 2017 · 75 d after period end